Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacotherapy. 2014 Mar;34(3):220-6. doi: 10.1002/phar.1341. Epub 2013 Aug 14.

Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.

Author information

1
Hoffmann-La Roche Inc., Nutley, New Jersey, United Kingdom.

Abstract

STUDY OBJECTIVE:

To investigate the steady-state pharmacokinetics of methadone when coadministered with ritonavir-boosted danoprevir (DNVr).

DESIGN:

Open-label, two-period, single-sequence pharmacokinetic study.

SETTING:

Two U.S. research centers.

PATIENTS:

Eighteen methadone-maintained healthy adults.

MEASUREMENTS AND MAIN RESULTS:

In Period 1 (Day -1), subjects received their daily methadone maintenance therapy (MMT). In Period 2 (Days 1-10), subjects received MMT plus DNVr 100/100 mg twice/day. Pharmacokinetic parameters for the total concentrations of (R)- and (S)-methadone on Days -1 and 10 were determined using noncompartmental methods. Unbound (R)- and (S)-methadone concentrations at 3 hours postdose were also assessed on Days -1 and 10. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) were used to compare steady-state (R)- and (S)-methadone pharmacokinetics when MMT was administered with or without DNVr. Methadone withdrawal was assessed using the Subjective Opiate Withdrawal Scale. Compared with MMT alone, methadone AUCtau and Cmax GMR (90% CI) following coadministration with DNVr were 1.02 (0.91-1.15) and 1.01 (0.90-1.13) for (R)-methadone, and 1.01 (0.90-1.13) and 0.99 (0.89-1.10) for (S)-methadone, respectively. Unbound (R- and (S)-methadone concentrations were comparable with or without DNVr. No instances of methadone withdrawal were reported. MMT in combination with DNVr was well tolerated.

CONCLUSION:

Coadministration of DNVr with MMT resulted in no significant pharmacokinetic interactions or signs of methadone withdrawal. No dosage adjustment is needed for MMT when coadministered with DNVr.

KEYWORDS:

HCV; methadone maintenance; pharmacokinetics; ritonavir-boosted danoprevir

PMID:
23946152
DOI:
10.1002/phar.1341
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center